Canada markets closed
  • S&P/TSX

    +107.96 (+0.56%)
  • S&P 500

    -10.56 (-0.25%)
  • DOW

    -54.34 (-0.16%)

    +0.0018 (+0.22%)

    +0.21 (+0.32%)

    -986.80 (-1.80%)
  • CMC Crypto 200

    +29.69 (+2.48%)

    +4.90 (+0.26%)
  • RUSSELL 2000

    +2.49 (+0.11%)
  • 10-Yr Bond

    +0.0050 (+0.31%)
  • NASDAQ futures

    +58.50 (+0.44%)

    +0.91 (+4.84%)
  • FTSE

    -10.76 (-0.15%)
  • NIKKEI 225

    +631.48 (+2.27%)

    +0.0008 (+0.12%)

Quanterix Webinar: Recent Advancements in Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test for Alzheimer’s Disease

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a webinar with leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. With several pharmaceutical companies making significant advances towards approval of Alzheimer's Disease therapies, this webinar discussion and live Q and A will further show the opportunity for blood plasma biomarkers combined with Simoa® technology to help advance Alzheimer’s clinical trials and diagnostics.

The webinar will take place on Friday, April 23, 2021 at 10:00am ET. The discussion will be led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and will feature Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg. Ph.D., University of Gothenberg.

To register for the webinar, visit

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on


Media Contacts:
PAN Communications
Staci Didner, 617-502-4300

Investor Relations Contact:
Stephen Hrusovsky
(774) 278-0496